BioNTech's Billion-Euro Gamble: Shareholders Endorse a Painful Pivot
Published on 05/17/2026 at 08:50 | Redaktion boerse-global.de
Shareholders gave BioNTech's management a ringing endorsement at the May 15 annual general meeting, approving all resolutions and granting full discharge to the board. The vote of confidence comes as the company navigates one of the most wrenching transitions in biotech: shedding its identity as a pandemic-era vaccine powerhouse to become a pure-play oncology group, a bet now costing hundreds of millions in losses and thousands of jobs.
The financial toll is mounting. In the first quarter of 2025, revenue collapsed to just €118.1 million as COVID-19 vaccine sales evaporated. The net loss ballooned to €531.9 million, compounding a full-year 2024 loss of €665 million on revenue of roughly €2.75 billion. Those figures reflect heavy spending on mRNA-based cancer research and restructuring charges at facilities including the US site in Gaithersburg, Maryland.
Cutting Costs to Fund the Future
Management is slashing costs aggressively to bridge the gap to profitability. Three production sites — in Idar-Oberstein, Marburg and Singapore — are slated for closure over the coming years, eliminating around 1,860 positions. From 2029 onward, the company expects annual savings of €500 million. That freed-up capital will flow directly into oncology R&D and shareholder returns; the board has announced a new share buyback programme of up to $1 billion.
Meanwhile, the remaining cash cushion remains formidable: BioNTech holds €16.8 billion in reserves, giving it ample runway to fund its pipeline through the lean years. The team left its full-year revenue forecast unchanged at €2.0 billion to €2.3 billion.
Should investors sell immediately? Or is it worth buying BioNTech?
Pipeline Progress and a Milestone Payment
Clinical momentum is building on two key late-stage assets — gotistobart and pumitamig. A milestone payment of €613 million is expected in the autumn from the existing partnership with Bristol Myers Squibb. The company is targeting the end of this year for the first market launch of a cancer immunotherapy, a development that could transform investor sentiment.
The stock, however, reflects the market's unease. On Friday, BioNTech shares closed at €76.95, down 2.22% on the day and roughly 8% lower month-on-month. The price stands nearly 25% below its 52-week high of €101.90, and only 6% above the year's trough of €72.50 — a position that screams skepticism.
Analysts Still Betting on a Recovery
Wall Street sees a different picture over a longer horizon. Eighteen analysts have set an average price target of $130.60, while another consensus puts it at $118.44 — both implying substantial upside from current levels. Those forecasts hinge on successful pipeline execution and the cost discipline now being implemented.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The next major test arrives on June 30, when BioNTech publishes its quarterly communication. Investors will scrutinise concrete clinical progress across the oncology candidates and early signs that the savings plan is taking hold. If the data disappoints, the gap between analyst optimism and the stock's reality could widen further. But if the transformation shows real traction, the billion-dollar bet may finally start to pay off.
Ad
BioNTech Stock: New Analysis - 17 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
